Walleye Capital’s Vivos Therapeutics VVOS Stock Holding History

Walleye Capital’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,000	Closed	-$743	–	1831
2021 Q2	$743	Buy	+6,000	New	+$977K	0.03%	573
2021 Q1	–	Sell	-2,980	Closed	-$440	–	1362
2020 Q4	$440	Buy	+2,980	New	+$544K	0.03%	516

Other funds holding VVOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIA

Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Walleye Capital's VVOS Position: Q3 2021 in Review

Walleye Capital sold out of Vivos Therapeutics (VVOS) in Q3 2021, closing a stake of 6,000 shares — an estimated $743 sold.

Walleye Capital first reported a position in VVOS in Q4 2020 and held it in 2 quarters. The position peaked at $743 in Q2 2021. 37 funds tracked by Wall St. Rank hold VVOS as of Q3 2021.

Walleye Capital reported no remaining Vivos Therapeutics position as of Q3 2021 after selling out during the quarter.
Walleye Capital sold 6,000 Vivos Therapeutics shares in Q3 2021, an estimated $743.
Walleye Capital first reported a position in Vivos Therapeutics in Q4 2020 and held it in 2 quarters.
Walleye Capital's Vivos Therapeutics position peaked at $743 in Q2 2021.
37 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2021.

Based on Walleye Capital's 13F filing for Q3 2021, filed 15 Nov 2021.